低密度脂蛋白导致动脉粥样硬化性心血管疾病：病理生理学、遗传学及治疗学见解：欧洲动脉粥样硬化学会共识小组的共识声明 - Suppr

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

作者信息

Borén Jan, Chapman M John, Krauss Ronald M, Packard Chris J, Bentzon Jacob F, Binder Christoph J, Daemen Mat J, Demer Linda L, Hegele Robert A, Nicholls Stephen J, Nordestgaard Børge G, Watts Gerald F, Bruckert Eric, Fazio Sergio, Ference Brian A, Graham Ian, Horton Jay D, Landmesser Ulf, Laufs Ulrich, Masana Luis, Pasterkamp Gerard, Raal Frederick J, Ray Kausik K, Schunkert Heribert, Taskinen Marja-Riitta, van de Sluis Bart, Wiklund Olov, Tokgozoglu Lale, Catapano Alberico L, Ginsberg Henry N

机构信息

Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.

Endocrinology-Metabolism Division, Pitié-Salpêtrière University Hospital, Sorbonne University, Paris, France.

出版信息

Eur Heart J. 2020 Jun 21;41(24):2313-2330. doi: 10.1093/eurheartj/ehz962.

DOI:10.1093/eurheartj/ehz962

PMID:32052833

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7308544/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c937/7308544/d72915e3f600/ehz962f8.jpg

相似文献

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2020 Jun 21;41(24):2313-2330. doi: 10.1093/eurheartj/ehz962.

A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.

Pharmacology. 2018;101(3-4):184-218. doi: 10.1159/000486374. Epub 2018 Jan 19.

[A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis].

Vnitr Lek. 2019 Winter;64(12):1124-1128.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Clin Chem. 2018 Jul;64(7):1006-1033. doi: 10.1373/clinchem.2018.287037. Epub 2018 May 14.

South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).

S Afr Med J. 2018 Oct 26;108(11b):973-1000.

Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies.

Nutrients. 2018 Nov 17;10(11):1789. doi: 10.3390/nu10111789.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.

Atherosclerosis. 2020 Feb;294:46-61. doi: 10.1016/j.atherosclerosis.2019.12.005. Epub 2020 Jan 9.

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.

Circ Res. 2016 Feb 19;118(4):547-63. doi: 10.1161/CIRCRESAHA.115.306249.

[Consensus on objectives and action guidelines on low density lipoproteins-cholesterol control in very high risk cardiovascular patients].

Clin Investig Arterioscler. 2016 Jan-Feb;28(1):31-42. doi: 10.1016/j.arteri.2015.09.002. Epub 2015 Dec 3.

[CME-Laboratory 61: New European Consensus Recommendations on Dyslipidemia].

Praxis (Bern 1994). 2020;109(3):215-220. doi: 10.1024/1661-8157/a003437.

引用本文的文献

Low-density lipoprotein cholesterol and clinical outcomes in patients with liver cirrhosis: a nationwide cohort study.

Ann Med. 2025 Dec;57(1):2551813. doi: 10.1080/07853890.2025.2551813. Epub 2025 Aug 30.

Low-Density Lipoprotein Cholesterol Target Attainment in Lithuania: A Nationwide Analysis of Real-World Health Data.

Medicina (Kaunas). 2025 Aug 19;61(8):1484. doi: 10.3390/medicina61081484.

Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features.

Life (Basel). 2025 Aug 3;15(8):1226. doi: 10.3390/life15081226.

A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part I.

Life (Basel). 2025 Jul 25;15(8):1185. doi: 10.3390/life15081185.

Effects of Novel Nutraceutical Combination on Lipid Pattern of Subjects with Sub-Optimal Blood Cholesterol Levels.

Biomedicines. 2025 Aug 9;13(8):1948. doi: 10.3390/biomedicines13081948.

The Clinical Value of Systemic Immune Inflammatory Index in Predicting the Prognosis of Patients with Bloodstream Infection.

J Inflamm Res. 2025 Jul 30;18:10181-10192. doi: 10.2147/JIR.S531272. eCollection 2025.

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach.

Eur J Med Res. 2025 Jul 30;30(1):690. doi: 10.1186/s40001-025-02937-1.

Associations Between Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Patients Undergoing Dialysis: A Nationwide Cohort Study.

J Clin Med. 2025 Jul 8;14(14):4845. doi: 10.3390/jcm14144845.

Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.

Int J Mol Sci. 2025 Jul 19;26(14):6950. doi: 10.3390/ijms26146950.

The Association of Histological Signs of Plaque Instability with Low eGFR, Higher Neutrophil-to-Lymphocyte Ratio, and Lower Serum MCP-1 Levels in Carotid Endarterectomy Patients-A Single-Center, Prospective Cohort Study.

Life (Basel). 2025 Jun 25;15(7):1008. doi: 10.3390/life15071008.

本文引用的文献

Clinical review on triglycerides.

Eur Heart J. 2020 Jan 1;41(1):99-109c. doi: 10.1093/eurheartj/ehz785.

Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies.

BMC Med. 2019 Nov 1;17(1):197. doi: 10.1186/s12916-019-1433-3.

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.

J Am Coll Cardiol. 2019 Oct 29;74(17):2132-2146. doi: 10.1016/j.jacc.2019.08.1024.

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.

N Engl J Med. 2019 Oct 17;381(16):1547-1556. doi: 10.1056/NEJMoa1816454.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

Plaque Calcification: Do Lipoproteins Have a Role?

Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):1902-1910. doi: 10.1161/ATVBAHA.119.311574. Epub 2019 Aug 29.

CAV1-CAVIN1-LC3B-mediated autophagy regulates high glucose-stimulated LDL transcytosis.

Autophagy. 2020 Jun;16(6):1111-1129. doi: 10.1080/15548627.2019.1659613. Epub 2019 Sep 4.

Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis.

Nat Med. 2019 Aug;25(8):1280-1289. doi: 10.1038/s41591-019-0512-5. Epub 2019 Jul 29.

Genetic Risk Score for Coronary Disease Identifies Predispositions to Cardiovascular and Noncardiovascular Diseases.

J Am Coll Cardiol. 2019 Jun 18;73(23):2932-2942. doi: 10.1016/j.jacc.2019.03.512.

SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis.

Nature. 2019 May;569(7757):565-569. doi: 10.1038/s41586-019-1140-4. Epub 2019 Apr 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献